Ikena Oncology (IKNA) Q2 2024 earnings summary

Executive summary

• Ikena Oncology is a clinical-stage targeted oncology company focused on therapies for cancer growth, spread, and resistance, with a primary focus on IK-595, a dual MEK-RAF inhibitor in Phase 1 trials as of June 2024.

• In 2024, the company underwent two major restructurings, reducing its workforce by 35% in January and 53% in May, discontinuing discovery efforts and the IK-930 program to focus on IK-595 and explore strategic alternatives.

• Ended Q2 2024 with $145.4 million in cash, cash equivalents, and marketable securities, supporting a strong financial position.

• Appointed Jotin Marango as COO in July 2024, in addition to his CFO and Head of Corporate Development roles.

• The company is actively exploring strategic options, including potential transactions, but there is no assurance of completion or benefit realization.

Financial highlights

• Net loss for Q2 2024 was $13.7 million, a 20% improvement from $17.1 million in Q2 2023; net loss for the six months ended June 30, 2024 was $29.9 million, down 5% year-over-year.

• Research and development expenses decreased 35% year-over-year to $9.8 million in Q2 2024, reflecting program prioritization and workforce reductions.

• General and administrative expenses remained flat at $5.3 million in Q2 2024.

• Restructuring and other charges were $0.7 million in Q2 2024.

• Cash, cash equivalents, and marketable securities totaled $145.4 million as of June 30, 2024.

Outlook and guidance

• Cash, cash equivalents, and marketable securities are expected to fund operations for at least 12 months from the filing date.

• The company anticipates continued operating losses as it advances IK-595 and explores strategic alternatives.

• Continues dose escalation in Phase 1 study of IK-595 for RAS and RAF mutant cancers, with promising early PK/PD activity.

• Future capital requirements depend on clinical progress, regulatory outcomes, and potential strategic transactions.

• Evaluating strategic options to maximize shareholder value following program discontinuation and restructuring.